Category: Companies

All Podcast Categories
S3-E52.2 - Efficacy of NITs and Predictive Outcomes

S3-E52.2 – Efficacy of NITs and Predictive Outcomes

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Ian shifts discussion toward the efficacy of various NITs and their predictive outcomes.

S3-E51.5 - From the Vault: AASLD 2021 Wrap-up

S3-E51.5 – From the Vault: AASLD 2021 Wrap-Up

The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th, 2022 in Washington DC. In this episode From the Vault, Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to promptly recap a just-concluded 2021 AASLD Annual Liver Meeting. Discussion centers around the many areas of advance and novelty in the program, with particular attention to non-invasive testing, genomics and the increased visibility of patients and their needs.

S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

S3-E51.3 – AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation explores patient advocate coverage of challenges facing liver health equity.

S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

S3-E51.2 – Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation focuses on fibrosis progression rates for diabetic vs. non-diabetic patients.

S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

S3-E51.1 – Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest.

S3-E51 - A Preview of the 2022 AASLD Liver Meeting

S3-E51 – A Preview of the 2022 AASLD Liver Meeting

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of key presentations and posters of interest.

S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage

S3-E50.5 – FIB-4 as a Front-Line Tool for Primary Care Triage

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver disease. This conversation explores the use of FIB-4 as a front-line tool for primary care. The advocates share their final thoughts on a change they can make in their country in the next 12 months that might extend beyond the country’s borders.

S3-E50.4 - Economics and Challenges of Pathway Design

S3-E50.4 – Economics and Challenges of Pathway Design

The panelists investigate the economics of pathway design within a wider discussion on the role of patient empowerment in putting a dent in Fatty Liver disease. This conversation observes challenges and opportunities for effective solutions.

S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools

S3-E50.2 – The Future of Digital Therapeutics and Patient Wellness Tools

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores the prospect of digital therapeutics as a Pharma-supported patient wellness tool.

Experience Nudge Learning! Interested in a new way of learning?